Daré Bioscience Reports Second Quarter 2019 Financial Results and Company Update
August 14, 2019 16:01 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the second quarter ended June 30, 2019...
Daré Bioscience Receives QIDP Designation from the FDA for DARE-BV1 for the Treatment of Bacterial Vaginosis
August 12, 2019 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that DARE-BV1, a novel thermosetting hydrogel containing...
Daré Announces Presentation of Positive Clinical Findings for Vaginal Administration of Novel Formulation of Clindamycin Phosphate for the Treatment of Bacterial Vaginosis at the 2019 Annual Meeting of the Infectious Diseases Society for Obstetrics and Gynecology
August 08, 2019 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the presentation of a poster at the upcoming annual meeting...
Daré Bioscience to Host Second Quarter 2019 Financial Results and Company Update Conference Call and Webcast
August 06, 2019 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30...
Daré Announces Presentation of Two Posters at the 2019 Controlled Release Society Annual Meeting & Exposition
July 22, 2019 08:00 ET
|
Dare Bioscience, Inc.
DARE-HRT1 is a potential treatment of menopause-related symptoms DARE-FRT1 is a potential pregnancy maintenance therapy SAN DIEGO, July 22, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc....
Daré Bioscience Announces 2019 AAPS Best Abstract Award for Vaginal Tamoxifen for Treatment of Vulvovaginal Atrophy: Pharmacokinetics and Safety in a Rabbit Model
July 17, 2019 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, July 17, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that it has received notification from the American...
Daré Bioscience Announces Appointment of Dr. William H. Rastetter as Chairman of the Board of Directors
July 15, 2019 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, July 15, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, announced today that William H. Rastetter, Ph.D., a current member of its...
Daré Bioscience Completes Recruitment in Pre-Pivotal Trial Of Monthly Woman-Controlled, Hormone-Free Contraceptive Candidate, Ovaprene®
June 26, 2019 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Calif., June 26, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced completion of patient recruitment in its...
Daré Bioscience, Inc. Announces Positive Results in Thermography Feasibility Study with Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder
June 17, 2019 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, June 17, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced positive findings from an investigational study designed to...
Daré Bioscience to Present at the 2019 BIO International Convention
May 29, 2019 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, May 29, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, President and Chief Executive Officer,...